Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To study serum level of leptin in patients with the metabolic syndrome (MS), including in patients with MS in combination with left ventricular hypertrophy (LVH) to determine the diagnostic significance of this marker in MS.

Material and methods. The study involved 43 patients with MS, 33 of them with signs of LVH, and 33 patients without MS comparable age, including 10 patients with LVH. The average age of patients in the MS group at the time of inclusion into the study was 62.7±10.3 years, in the control group (without MS) – 60±14.7 years. All patients underwent a comprehensive examination that included the collection of complaints, study of history, physical examination, anthropometric measurements, laboratory and instrumental examination, including study of the serum level of leptin.

Results. Patients of both groups had statistically significant differences in the size of the heart chambers, the presence of LVH signs, left ventricle contractile function, the thickness of the epicardial fat layer. Thus, enlargement of the heart, thickness of the interventricular septum, posterior wall of the left ventricle, thickness of epicardial fat, reduction of ejection fraction of the left ventricle and characteristics of aortic atherosclerosis were observed significantly more often in patients with MS compared with the group without MS (p<0.05).The average serum level of leptin in the MS group (41.89±33.28 ng/ml) was significantly higher compared to the group without MS (17.64±16.87 ng/ml), p<0.001. At that women had significantly higher levels of serum leptin (38.65±29.23 ng/ml) compared to males (19.54±27.23 ng/ml), p=0.006. A positive correlation between leptin levels and symptoms of LVH (r=0.294, p<0.001) was revealed: in the absence of LVH average level of leptin was 21.7±4.1 ng/ml, in the presence of signs of LVH – 39.2±4.95 ng/ml.

Conclusions. Leptin levels in MS patients is higher than in patients without MS, and in patients with MS associated with LVH is higher than in MS patients without LVH. As the leptin level increases, the risk of LVH increases.

About the Authors

O. M. Drapkina
National Medical Research Center for Preventive Medicine
Russian Federation

Oksana M. Drapkina – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director 

Petroverigsky per. 103, Moscow, 101990

R. N. Shepel
National Medical Research Center for Preventive Medicine
Russian Federation

 Ruslan N. Shepel – MD, Junior Researcher, Department of Fundamental and Applied Aspects of Obesity

Petroverigsky per. 103, Moscow, 101990

T. A. Deeva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Tatyana A. Deeva – MD, Postgraduate Student, Chair of Internal Medicine Propaedeutics

Trubetskaya ul. 8, Moscow, 119991


1. Drapkina O.M., Eliashevich S.O., Shepel R.N. Obesity is a risk factor for chronic noncommunicable diseases. Russian Journal of Cardiology. 2016;6:73-9. (In Russ.) [Драпкина О.М., Елиашевич С.О., Шепель Р.Н. Ожирение как фактор риска хронических неинфекционных заболеваний. Российский Кардиологический Журнал. 2016;6:73-9]. doi: 10.15829/1560-4071-2016-6.

2. Wong R.J., Chou C., Sinha S.R., et al. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health. 2014;39:437-45. doi:10.1007/s10900-0139792-8.

3. Saydah S., Bullard K.M., Cheng Y., et al. Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999-2010. Obesity (Silver Spring). 2014;22(8):1888-95. doi: 10.1002/oby.20761.

4. Russian guidelines for management of patients with metabolic syndrome (2013). Available at: Checked by 11/02/2018 (In Russ.) [Российские рекомендации по ведению больных с метаболическим синдромом (2013). Доступно на: Проверено 11.02.2018].

5. Schillaci G., Verdecchia P., Porcellati C., et al. Continuous Relation Between Left Ventricular Mass and Cardiovascular Risk in Essential Hypertension. Hypertension. 2000;35:580-6. doi: 10.1161/01.HYP.35.2.580.

6. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronaryartery disease: a workshop consensus statement. Am Heart J. 1991;121:1244-63. doi: 10.1016/00028703(91)90694-D.

7. Ametov A.S., Demidova T.Yu., Tselikovskaya A.L. Effect of leptin on the regulation of body weight. Serdechnaja Nedostatochnost'. 2001;2(3):309-11. (In Russ.) [Аметов А.С., Демидова Т.Ю., Целиковская А.Л. Влияние лептина на регуляцию массы тела. Сердечная Недостаточность. 2001; 2(3): 30911].

8. Coppack S.W. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001; 60: 349-356.

9. Chearskul S., Kooptiwut S., Pummoung S., et al. Obesity and appetite-related hormones. J Med Assoc Thai. 2012;95(11):1472-9.

10. Purdham D.M., Zou M.X., Rajapurohitam V., Karmazyn M. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol. 2004;287:2877-84. doi: 10.1152/ajpheart.00499.2004.

11. Rajapurohitam V., Gan X.T., Kirshenbaum L.A., Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res. 2003;93:277-9. doi: 10.1161/01.RES.0000089255.37804.72.

12. Schulze P.C., Kratzsch J., Linke A., et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail. 2003;5:33-40. doi: 10.1016/S13889842(02)00177-0.

13. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens. 2006;23:789-801. doi: 10.1097/01.hjh.0000222743.06584.66

14. Alberti K.G., Zimmet P., Shaw J. The Metabolic Syndrome A new worldwide definition from the International Diabetes Federation Consensus. Lancet. 2005; 366: 1059-62. doi: 10.1111/j.14645491.2006.01858.x.

15. Vasyuk Yu.A., Sadulayeva IA, Yushchuk E.N. et al. Metabolic syndrome: new aspects of the old problem. Arterial'naja Gipertenzija. 2007; 13 (2): 34-6. (In Russ.) [Васюк Ю.А., Садулаева И.А., Ющук Е.Н. и др. Метаболический синдром: новые аспекты старой проблемы. Артериальная Гипертензия. 2007;13(2):34-6].

16. Drapkina O.M., Shepel R.N., Deeva T.A. Assessment of leptin level in patients with metabolic syndrome and coronary heart disease. Cardiovascular Therapy and Prevention. 2016;15(3):43-8. (In Russ.) [Драпкина О. М., Шепель Р. Н., Деева Т. А. Оценка уровня лептина у пациентов с метаболическим синдромом и ишемической болезнью сердца. Кардиоваскулярная Терапия и Профилактика. 2016;15(3):43-8]. doi:10.15829/1728-8800-2016-3-43-48.

17. Dagogo-Jack S., Fanelli C., Paramore D., et al. Plasma leptin and insulin relationships in obese and nonobese humans. Diabetes. 1996;45:695-8. doi: 10.2337/diab.45.5.695.

18. Drapkina O.M., Deeva T.A., Popova I.R. Non-alcoholic fatty liver disease as an obligate sign of obesity. Rossijskie Medicinskie Vesti. 2012;17(4):4-10. (In Russ.) [Драпкина О.М., Деева Т.А., Попова И.Р. Неалкогольная жировая болезнь печени как облигатный признак ожирения. Российские Медицинские Вести. 2012;17(4):4-10].

19. Abe Y., Ono K., Kawamura T., et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol. 2007;292(5):238796. doi: 10.1152/ajpheart.00579.2006

20. Wallace A.M., McMahon A.D., Packard C.J., Kelly A., Shepherd J., Gaw A. et al. Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001; 104:3052-3056.

21. Chen M.S., Wang Y.Z., Yi Q, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation. 2004;110:1269-75. doi: 10.1161/01.CIR.0000140766.52771.6D.

22. Correia M.L., Haynes W.G. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens. 2004;13(2):215-23.


For citations:


Views: 507

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)